Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE AF versus ESMOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE AF versus ESMOLOL HYDROCHLORIDE.
BETAPACE AF vs ESMOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sotalol is a class III antiarrhythmic agent that also has non-cardioselective beta-adrenergic receptor blocking activity. It prolongs the cardiac action potential duration by blocking potassium channels (IKr), thereby prolonging the QT interval and refractory periods.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
80 mg orally twice daily. For atrial fibrillation/flutter, initiate at 80 mg twice daily; may increase after 2-3 days to 120 mg twice daily if needed. Maximum 120 mg twice daily.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min; titrate by 25-50 mcg/kg/min every 5-10 minutes up to 200 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–20 hours) in patients with normal renal function; prolonged in renal impairment (up to 42 hours in severe impairment).
Terminal elimination half-life: approximately 9 minutes in adults (range 4–13 min); in patients with hepatic impairment: unchanged; in severe renal impairment: prolonged to 12–20 min due to metabolite accumulation. Clinically, rapid offset (within 20–30 min) allows for titration.
Primarily renal (unchanged drug and metabolites); approximately 40% excreted as unchanged sotalol in urine, with additional metabolites via fecal route (~10%). Biliary excretion minimal (<5%).
Rapid metabolism by red blood cell esterases to inactive acid metabolite (ASL-8123) and methanol; <2% excreted unchanged in urine; primarily renal elimination of metabolites.
Category C
Category A/B
Beta-Blocker
Beta-Blocker